Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers

International Journal of Cardiology

Volumn 136, Issue 2, 2009, Pages 222-225

  Pineda, Javier ^a   Marín, Francisco ^a   Marco, Pascual ^a   Roldán, Vanessa ^b   Valencia, José ^a   Ruiz Nodar, Juan M ^a   Sogorb, Francisco ^a   Lip, Gregory Y H ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Haemostatic; Myocardial infarction; Thrombophilia; Young

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; FIBRIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PREMATURE CORONARY ARTERY DISEASE; PRIORITY JOURNAL; SAMPLE SIZE; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS; UNIVARIATE ANALYSIS;

ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; HUMANS; LIPIDS; MIDDLE AGED; THROMBOPHILIA;

EID: 67650770305     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.04.020     Document Type: Article

References (29)

1. Lee K., and Lip G.Y.H. Acute coronary syndromes: Virchow's triad revisited. Blood Coagul Fibrinolysis 14 (2003) 1-21
2. Pineda J., Marín F., Roldán V., Valencia J., Marco P., and Sogorb F. Premature myocardial infarction: clinical profile and angiographic findings. Int J Cardiol 126 (2008) 127-129
3. Chen L., Chester M., and Kaski J. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 108 (1995) 364-369
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022
5. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 (2002) 1202-1206
6. Cleophas T.J., Hornstra N., van Hoogstraten B., and van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 86 (2000) 1005-1009
7. Al-Obaidi M.K., Stubbs P.J., Collinson P., Conroy R., Graham I., and Noble M.I. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol 36 (2000) 1217-1222
8. Kaul S., Zadeh A.A., and Shah P.K. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 48 (2006) 914-923
9. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 (2000) 1082-1085
10. Bostom A.G., Cupples L.A., Jenner J.L., et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 276 (1996) 544-548
11. Alfthan G., Pekkanen J., Jauhiainen M., et al. Relation of serum homocyst(e)ine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106 (1994) 9-19
12. Ridker P.M. An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. Trends Cardiovasc Med 5 (1995) 225-229
13. Hahmann H.W., Schätzer-Klotz D., Bunte T., Becker D., and Schieffer H.J. The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: differences between men and women. Atherosclerosis 144 (1999) 221-228
14. Foody J., Milberg J., Robinson K., Pearce G.L., Jacobsen D.W., and Sprecher D.L. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 20 (2000) 493-499
15. Vaarala O., Manttari M., Manninen V., Tenkanen L., Puurunen M., Aho K., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91 (1995) 23-27
16. Folsom A. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 86 (2001) 366-373
17. Hoffmeister A., Rothenbacher D., Bäzner U., Fröhlich M., Brenner H., Hombach V., et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 87 (2001) 262-266
18. Ernst E., and Resch K. Fibrinogen as cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118 (1993) 956-963
19. Maresca G., Di Blasio A., Marchioli R., and Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 19 (1999) 1368-1377
20. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 19 Suppl C (1998) C39-C43
21. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89 (2003) 601-609
22. Lowe G., Yarnell J., Sweetnam P., Rumley A., Thomas H.F., and Elwood P.C. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Heamost 79 (1998) 129-133
23. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., and Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21 (2001) 611-617
24. Whincup P.H., Danesh J., Walker M., et al. Von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 23 (2002) 1764-1770
25. Smith F.B., Lee A.J., Fowkes F.G., Price J.F., Rumley A., and Lowe G.D. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 17 (1997) 3321-3325
26. Thögersen A., Jansson J., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
27. Lowe G., Danesh J., Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25 (2004) 252-259
28. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321 (2000) 199-204
29. Plenge J.K., Hernandez T.L., Weil K.M., Poirier P., Grunwald G.K., Marcovina S.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452